Table 2.
Expression of SST2A and SST3 in conditions represented by more than 20 cores.
| Diagnosis | TMA ID | SST2A+/3– % (n) | SST3+/2A– % (n) | SST2A+/3+ % (n) | SST2A–/3– % (n) |
|---|---|---|---|---|---|
| Bone giant cell tumor (n = 40) | BO2081 | 2.5% (1) | 5.0% (2) | 85.0% (34) | 7.5% (3) |
| Adrenocortical adenoma (n = 40) | AG801 | 5% (2) | 22.5% (9) | 65% (26) | 7.5% (3) |
| Osteosarcoma (n = 52) | BO2081 | 7.7% (4) | 48.1% (25) | 34.6% (18) | 9.6% (5) |
| Malignant melanoma (n = 176) | ME2082d | 2.3% (4) | 44.9% (79) | 43.2% (76) | 9.7% (17) |
| Benign pheochromocytoma (n = 30) | AG801 | 0.0% (0) | 56.7% (17) | 30.0% (9) | 13.3% (4) |
| Metastatic hepatocellular carcinoma (n = 34) | LV1221 | 5.9% (2) | 52.9% (18) | 20.6% (7) | 20.6% (7) |
| Pelvic urothelial carcinoma (n = 26) | KD2001 | 34.6% (9) | 30.8% (8) | 11.5% (3) | 23.1% (6) |
| Carcinoid (n = 21) | NE841, LV1221 | 0.0% (0) | 47.6% (10) | 28.6% (6) | 23.8% (5) |
| Hepatocellular carcinoma stages I-IIIa (n = 136) | LV1221a, BC000120b, LV1221 | 4.4% (6) | 59.5% (81) | 10.3% (14) | 25.7% (35) |
| Lymph node diffuse large B cell lymphoma (DLBL) (n = 30) | LY301 | 23.3% (7) | 33.3% (10) | 13.3% (4) | 30.0% (9) |
| Chondrosarcoma (n = 20) | BO2081 | 0.0% (0) | 55.0% (11) | 5.0% (1) | 40.0% (8) |
| Hepatocellular carcinoma stage IV (n = 28) | LV1221 | 9.7% (3) | 38.7% (11) | 6.4% (1) | 45.2% (13) |
| Endometroid adenocarcinoma (n = 38) | BC000120b | 0.0% (0) | 42.1% (16) | 7.9% (3) | 50.0% (19) |
| Intrahepatic cholangiocarcinoma (n = 40) | LV1221 | 25.0% (10) | 17.5% (7) | 5.0% (2) | 52.5% (21) |
| Ovarian adenocarcinoma (n = 38) | BC000120b | 5.3% (2) | 36.8% (14) | 2.6% (1) | 55.3% (21) |
| Renal clear cell carcinoma (n = 138) | KD2001 | 5.1% (7) | 26.8% (37) | 6.5% (9) | 61.6% (85) |
| Gastric adenocarcinoma (n = 37) | BC000120b | 8.1% (3) | 13.5% (5) | 0.0% (0) | 78.4% (29) |
| Head and neck squamous cell carcinoma (n = 38) | BC000120b | 2.6% (1) | 18.4% (7) | 0.0% (0) | 78.9% (30) |
Numbers indicate the number of cores found utilitarianly positive for the respective receptor expression (IRS ≥ 6). The co-expression has been determined when both receptors on the same core were positive (IRS ≥ 6).